NASD · Healthcare · Biotechnology · Canada
Aurinia Pharmaceuticals Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Aurinia develops and sells LUPKYNIS, an oral medication for treating active lupus nephritis in adult patients. The company distributes the drug through specialty pharmacies in the United States and via a collaboration partner in Europe and Japan. Aurinia also has aritinercept in development, a dual inhibitor for potential autoimmune disease treatment.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Aurinia Pharmaceuticals Inc stock.
Undervalued: intrinsic value $38.92 per share, market price $16.65, margin of safety 57.2% (as of 2026-10-30).
Discounting its cash flows at 11.3% (average of 3 methods) values the shares at $38.92; the price of $16.65 is 57% below that value, and 71% of that value comes from beyond year five.
Leak Score: 93/100 on 10 of 12 signals (Major Leak).
17 more funds hold it; the full list is part of the paid plan.
3 more in this industry show a wider margin of safety.
AUPH is undervalued (as of the 2026-10-30 close). Discounting its cash flows at 11.3% (average of 3 methods) values the shares at $38.92; the price of $16.65 is 57% below that value, and 71% of that value comes from beyond year five.
$38.92 per share (as of the 2026-10-30 close), against a market price of $16.65. That is a margin of safety of 57.2%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
93 out of 100, which we rate "Major Leak", on 10 of 12 value investing signals.